Concepts of Risk in Nanomedicine Research

Abstract

Risk takes center stage in ethical debates over nanomedical technologies. Yet concepts of risk may hold different meanings, and they are embedded within particular political, economic, and social contexts. This article discusses framings of risk in debates over medical innovations such as nanomedicine, and draws attention to organizational and institutional forms of risk which are less visible in bioethical policy debates. While significant, possibly unique risks may exist in specific nano-based products, risk may also arise from the very processes and procedures that develop, test, and oversee any novel technology. This supports recommendations to coordinate efforts through an interagency Working Group and a Secretary-level Advisory Committee to provide flexibility and sensitivity to emerging issues of concern.

Business Risk Mitigation in the Development Process of New Monoclonal Antibody Drug Conjugates for Cancer Treatment

“…In the case of ADCs, toxicological analyses are typically the first thing that comes to mind when assessing risk, as they are critical for evaluating the safety of these molecules. There is a significant body of literature on toxicological risk analysis for ADCs, and many new methodologies have been developed and published [ 75 , 76 , 77 ]. However, business risk methodologies for the development of these molecules have been less discussed.…”

Which Nanobasics Should Be Taught in Medical Schools?

“…This increased risk has implications for informed consent in clinical trials. [56][57][58][59][60] For example, the occurrence of side effects may be delayed, given that some nanotechnology platforms, such as nanogold, can accumulate in tissues and persist longer than traditional medicines. 61 As a result, some side effects might not be captured during the trial itself or even during the first few years of postapproval long-term safety monitoring.…”

Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies

“…An elevated degree of unpredictability about prospective hazards and true advantages of NPs and nanomedicines, however, created remarkable obstacles along this translational pathway (Resnik and Tinkle, 2007 ). As such, nanotechnological approaches have opened up a few issues with respect to their proper risk assessment and risk minimization (Hogle, 2012 ), with particular emphasis on human and environmental toxicity (Allhoff, 2009 ; Ramachandran et al, 2012 ). Especially compelling in this respect are “first in human” (FIH) trials of nanotechnology medical applications, as they raise the highest degree of unpredictability in all clinical area (Kimmelman and John London, 2011 ).…”